Cyclopharm (ASX: CYC) is heading for regulatory approvals for its newly developed proprietary patented technology, Ultralute, that will enable nuclear medicine departments to dramatically improve their operating efficiencies and health outcomes for patients.
The Ultralute technology extends the useful life of Mollybdenum-99 generators, the world’s most common nuclear medicine radioisotope and a precursor to the Technetium-99m (Tc-99m) isotope, by up to an additional 50%.
Tc-99m is the primary isotope used in diagnostic imaging throughout the world accounting for about 80% of all procedures performed in nuclear medicine today.
Applications include cardiac, bone, liver, brain, renal and lung imaging.
Initial testing and prototype designs of the Ultralute technology have provided highly positive results.
Cyclopharm is now moving toward the regulatory approval process and at the same time has entered into discussions with potential commercial partners.
The company had around A$2.3 million in cash at the end of December 2012.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.